Item | Number % |
Gender Male Female |
21 (48.8%) 22 (51.2%) |
Age Range (years) Mean ± SD |
40 - 70 55.9 ± 9.2 |
Smoking Yes No |
21 (48.8%) 22 (51.2%) |
Performance status 0/1 2 |
28 (65.1%) 15 (34.9%) |
Sites Larynx Oropharynx Hypopharynx |
26 (60.5%) 10 (23.3%) 7 (16.2%) |
Subsites Glottic Supraglottic Tongue Post cricoid |
15 (34.9%) 11 (25.6%) 11 (25.6%) 6 (13.9%) |
Tumor size T1 T2 T3 T4 |
0 (0%) 21 (48.8%) 17 (39.6%) 5 (11.6%) |
Lymph nodes N0 N1 N2 N3 |
15 (34.9%) 15 (34.9%) 9 (20.9%) 4 (9%.3) |
Stage II III Iva&b |
15 (34.9%) 9 (20.9%) 19 (44.1%) |
Treatment modalities Definitive radiotherapy Induction chemotherapy followed by CCRTH CCRTH |
15 (34.9%) 9 (20.9%) 19 (44.1%) |